Lisbon, Portugal—A deep lamellar keratoplasty (DLKP) procedure that exposes Descemet's membrane seems safe and effective to correct keratoconus, according to Mohamed Alaa El-Danasoury, MD, who reported his group's 1-year experience with the procedure.
New York—The New York Eye & Ear Infirmary (NYEEI) celebrated its 185th anniversary with the "Thanks for Giving" Ball and three award presentations.
Lake Forest, CA—IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.
Chicago—Results of the 2005 International Society of Refractive Surgery (ISRS)/American Academy of Ophthalmology (AAO) survey highlight some interesting trends in refractive surgery across the United States, said Richard J. Duffey, MD, at the refractive subspecialty meeting sponsored by the ISRS/AAO.
Lisbon, Portugal—The use of fibrin glue seems to be effective and safe in total anterior lamellar keratoplasty (TALK), a procedure that completely exposes Descemet's membrane within the area of host corneal trephination. Thomas John, MD, explained the procedure, which involves the transplantation of donor cornea without Descemet's membrane and endothelium, at the European Society of Cataract and Refractive Surgeons annual meeting.
Washington, DC—Physicians nationwide, including ophthalmologists, will endure a 4.4% reduction in reimbursements effective Jan. 1 in light of the Centers for Medicare and Medicaid Services' (CMS) newly released 2006 Physician Fee Schedule.
Washington, DC—Two years after a Cleveland ophthalmologist began lobbying Congress to regulate cosmetic contact lenses as medical devices, the bill is on its way to the president's desk for a signature.
Long-term follow-up and a controlled trial of PRK with adjunctive mitomycin-C after PKP compared with LASIK after PKP for keratoconus are needed.
With surface ablation procedures becoming more common, surgeons have developed a combination therapy management approach including a fluoroquinolone antibiotic, a nonster-oidal anti-inflammatory drug (NSAID), and a steroid to prevent infection and reduce pain.
Los Angeles—Results from the Xibrom First Experience (XFE) trial show that the new twice-a-day nonsteroidal anti-inflammatory drug (NSAID) is being well received by cataract surgeons and their patients alike, said David F. Chang, MD.
Chicago—After topical administration, moxifloxacin 0.5% (Vigamox, Alcon Laboratories) penetrates better into the cornea than gatifloxacin 0.3% (Zymar, Allergan) to achieve significantly higher levels in the epithelium and stroma, reported Terry Kim, MD, at the annual meeting of the Ocular Microbiology and Immunology Group.
Chicago—Nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) is a significant advance in the treatment of pain and inflammation associated with cataract surgery. The nonsteroidal anti-inflammatory prodrug offers well-tolerated, effective, target-specific therapy that may enhance patient compliance and quality of vision outcomes, said Robert P. Lehmann, MD, FACS, at the annual meeting of the American Academy of Ophthalmology.
Valhalla, NY—The management of endophthalmitis has progressed in leaps and bounds over the past 4 decades. Immediate treatment, however, is vision-saving, with many patients achieving 20/40 vision.
Chicago-A number of advances have been made in the ability to diagnose and manage optic nerve sheath meningiomas. Neil R. Miller, MD, described how best to handle these tumors during the William F. Hoyt Lecture at the American Academy of Ophthalmology annual meeting.
With cataract and refractive procedures, ocular comfort and inflammation management are highly relevant to the patient's impression of a successful procedure. Add to that an expectation that an increase in visual acuity will follow closely on the heels of surgery, and the standards are set very high.
Glaucoma presents a significant challenge for researchers seeking to adapt what is learned about genetics in labs to strategies that can be used in patient care.
Following are some software products available for evaluation.
Montr?al—Oral moxifloxacin (Avelox, Bayer) can penetrate into the vitreous at a level that can kill most common pathogens in the eye. This drug, a fluoroquinolone, may play a role in the treatment or prevention of endophthalmitis.
A new and promising therapeutic approach to treating diseases in which abnormal protein production is a problem, including AMD, is known as RNA interference (RNAi). RNAi is a biological method of turning off specific disease-causing genes and is being tested in at least two trials involving patients with AMD.
Chicago—The Age-Related Eye Disease Study II (AREDS II) will begin soon after the initial AREDS concludes next month.
La Jolla, CA—Many optic disc measurements obtained using confocal scanning laser ophthalmoscopy (CSLO) can help predict the development of primary open-angle glaucoma (POAG) in patients with ocular hypertension, according to the recently published results of an ancillary study to the National Eye Institute (NEI)-sponsored Ocular Hypertension Treatment Study (OHTS).
Washington, DC—Legislators on Capitol Hill heard first-hand how their funding of National Eye Institute (NEI) research is advancing the understanding of age-related macular degeneration (AMD).
La Jolla, CA—Many optic disc measurements obtained using confocal scanning laser ophthalmoscopy (CSLO) can help predict the development of primary open-angle glaucoma (POAG) in patients with ocular hypertension, according to the recently published results of an ancillary study to the National Eye Institute (NEI)-sponsored Ocular Hypertension Treatment Study (OHTS).
Montr?al—A visual prosthetic device used to treat visual loss resulting from end-stage age-related macular degeneration (AMD) is providing patients with clinically meaningful increases in vision and quality of life.
Newport Beach, CA—Imaging technology for quantitative assessment of the optic nerve and retinal nerve fiber layer (RNFL) can be a useful supplemental tool to clinicians, especially when the diagnosis of glaucoma is uncertain based on other clinical information, said Donald L. Budenz, MD, MPH, at Innovations in Glaucoma.
While fluorescein angiograms and optical coherence tomography can assess structure, the retinal acuity meter looks at function.
Nidek has released new diagnostic software called the OPD-Station that lets clinicians use data from its OPD-Scan device to perform a variety of corneal, total eye, and internal eye analyses using several sophisticated new functions.
Newport Beach, CA—White-on-white perimetry remains the gold standard for functional testing in glaucoma management, but that methodology has been improved by some recent software developments, and other new functional tests can be useful supplements for patient evaluation, said Donald L. Budenz, MD, MPH.
Rockville, MD—A researcher who has worked to determine the pathogenesis of age-related macular degeneration will receive the Association for Research in Vision and Ophthalmology's (ARVO) 2006 Cogan Award.
Washington, DC—Legislators on Capitol Hill heard first-hand how their funding of National Eye Institute (NEI) research is advancing the understanding of age-related macular degeneration (AMD).
